Consequences of stroke and AF

Similar documents
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?

MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC

Atrial Fibrillation & Acute Stroke

IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital

GRASP-AF- The National Picture. Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012

Atrial Fibrillation Key Messages

Atrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto

Modern management of atrial fibrillation, from blood pressure control to anticoagulation

NeuroPI Case Study: Anticoagulant Therapy

NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna

KCS Congress: Impact through collaboration

Real-World Insights from GARFIELD-AF Registry Presented at ESC Congress 2017

Results from RE-LY and RELY-ABLE

A COhort of antithrombotic use and. atrial fibrillation in Thailand (COOL AF Thailand)

Prof. Fiorenzo Gaita

What s New in the AF Guidelines

Updates in Atrial Fibrillation

Updates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy

Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland

Controversies in Risk Stratification

US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation

Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France

Reversal Agents for NOACs (Novel Oral Anticoagulants)

Professor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham

I have nothing to disclose.

ACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter

Mohammad Zubaid, MB, ChB, FRCPC, FACC

Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근

Atrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal

Left Atrial Appendage Closure: The Rationale

Anti-thromboticthrombotic drugs

Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES

NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli

Table S10 Mortality Study

Antithrombotics in Stroke management

V. Roldán, F. Marín, B. Muiña, E. Jover, C. Muñoz-Esparza, M. Valdés, V. Vicente, GYH. Lip

Evaluate Risk of Stroke & Bleeding in AF Patients

Antithrombotic Therapy in Patients with Atrial Fibrillation

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

A Patient with Chest Pain and Atrial Fibrillation

Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?

A Patient Unsuitable for VKA Treatment

In Whom and When Should Atrial Fibrillation Ablation be Considered?

New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy

Thrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy

6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia

AF stroke prevention in the Canadian context

Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger

Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers

Secondary Stroke Prevention: A Precautionary Tale

Objectives. Falling Down on Warfarin Therapy. CHADS 2 Score. CHADS 2 & CHA 2 DS 2 -VASc Score. HAS-BLED Score 04/08/2014. Real World Application

Atrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018

Aims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

HAS-BLED. Ron Pisters, MD Maastricht University Medical Centre (NL) No conflict of interest

Atrial fibrillation: a key determinant in the cardiovascular risk continuum. u Prof. Joseph S. Alpert u Arizona, USA

Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto

2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation

ADVANCES IN ANTICOAGULATION

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION

Stepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg

Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen

Atrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018

Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de

controversies in anticoagulation: optimizing outcome for atrial fibrillation

Do Not Cite. Draft for Work Group Review.

Draft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011

Atrial fibrillation and advanced age

Study period Total sample size (% women) 899 (37.7%) Warfarin Aspirin

Devices to Protect Against Stroke in Atrial Fibrillation

How atrial fibrillation should be treated in the heart failure patient?

Management of atrial fibrillation a holistic view - Prof. Dr. Martin Borggrefe Mannheim

Off beat: Atrial fibrillation and the cost of preventable strokes

ATRIAL FIBRILLATION AROUND THE WORLD/ CONTINENTAL PERSPECTIVES AND SPECIFICITIES: SOUTH AMERICA. LUIS AGUINAGA MD, PhD, FESC,FACC Argentina

What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen

Subclinical AF: Implications of device based episodes

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Atrial Fibrillation and Heart Failure: A Cause or a Consequence

Primary Prevention of Stroke

AF Stroke Prevention Through Screening, Intervention and Patient Choice

Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016

Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016

What are the risk factors for AF?

Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust

Reducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA

Secondary Stroke Prevention

ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE

ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ

NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING

Atrial Fibrillation Management in the ED. J Fisher May 2014"

Management and Investigation of Ischemic Stroke By Etiology

Anticoagulation Therapy: for a New Paradigm

ACCP Cardiology PRN Journal Club

Current Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine

Transcription:

Consequences of stroke and AF Lorenzo G Mantovani Center of Pharmacoeconomics University of Naples Center for Public Health Research University of Milan Bicocca

Questions Is stroke frequent? Is stroke a burden? Is AF a cause of stroke? Is AF frequent? Can we prevent Stroke due to AF? (theory) Can we prevent Stroke due to AF? (practice) Who is candidate for new OAC? How many candidates do we have? Is it value for money (theory)? Is it value for money (practice)?

Questions Is stroke frequent? Is stroke a burden? Is AF a cause of stroke? Is AF frequent? Can we prevent Stroke due to AF? (theory) Can we prevent Stroke due to AF? (practice) Who is candidate for new OAC? How many candidates do we have? Is it value for money (theory)? Is it value for money (practice)?

YES Incidence 2-3 events per 1000 py s Italy 150k events per year* *Italian Source: Ministry of Health

Questions Is stroke frequent? Is stroke a burden? Is AF a cause of stroke? Is AF frequent? Can we prevent Stroke due to AF? (theory) Can we prevent Stroke due to AF? (practice) Who is candidate for new OAC? How many candidates do we have? Is it value for money Is it value for money (theory)? Is it value for money (practice)?

YES Incident stroke first year cost Health care 5.5k Non health care 4.5k Indirect 1k 11k Euro s

Questions Is stroke frequent? Is stroke a burden? Is AF a cause of stroke? Is AF frequent? Can we prevent Stroke due to AF? (theory) Can we prevent Stroke due to AF? (practice) Who is candidate for new OAC? How many candidates do we have? Is it value for money (theory)? Is it value for money (practice)?

YES

AND VERY MUCH SO

AF=atrial fibrillation; OR=odds ratio; CI=confidence interval 1. Lin HJ, et al. Stroke 1996; 27: 1760 4; 2. Dulli DA, et al. Neuroepidemiology 2003; 22: 118 23 Survival is poorer and stroke recurrence rates are higher following AF-related stroke Framingham (10-year follow up from 1981) 1-year post stroke recurrence 30-day post stroke mortality 1-year post stroke mortality AF patients (n=30) Non-AF patients (n=120) 23% 8% 30% 17% 63% 34%

Patients bedridden on admission (%) AF=atrial fibrillation; OR=odds ratio; CI=confidence interval Dulli DA, et al. Neuroepidemiology 2003; 22: 118 23 Functional outcomes of stroke are significantly worse in patients with AF, and more patients remain bedridden 50 40 30 20 41.2% OR for bedridden state following stroke due to AF was 2.23 (95% CI: 1.87, 2.59) p<0.0005 23.7% 10 0 With AF (n=194) Without AF (n=867)

Questions Is stroke frequent? Is stroke a burden? Is AF a cause of stroke? Is AF frequent? Can we prevent Stroke due to AF? (theory) Can we prevent Stroke due to AF? (practice) Who is candidate for new OAC? How many candidates do we have? Is it value for money (theory)? Is it value for money (practice)?

1+ million prevalent subjects 130.00 new cases per year

Atrial Fibrillation (AF) AF is the most common heart rhythm disturbance 1 It is estimated that 1 in 4 individuals aged 40 years will develop AF 1 In 2007, 6.3 million people in the US, Japan, Germany, Italy, Spain, France, and UK were living with diagnosed AF 2 Due to the aging population, this number is expected to double within 30 years 3 1. Lloyd-Jones DM et al. Circulation 2004;110:1042-1046. 2. Decision Resources. Atrial Fibrillation Report. Dec 2008. 3. Go AS et al. JAMA. 2001;285:2370-2375.

Rationale for Stroke Prevention in Patients With AF AF increases the risk for stroke 5-fold 1 The increase in risk for stroke is similar for paroxysmal, persistent, and permanent AF 2 Strokes associated with AF are usually more severe than those from other causes, conferring an increased risk for morbidity, mortality, and poor functional outcome 2 1. Wolf PA et al. Arch Intern Med. 1987;147(9):1561-1564. 2. Savelieva I et al. Ann Med. 2007;39(5):371-391.

Questions Is stroke frequent? Is stroke a burden? Is AF a cause of stroke? Is AF frequent? Can we prevent Stroke due to AF? (theory) Can we prevent Stroke due to AF? (practice) Who is candidate for new OAC? How many candidates do we have? Is it value for money (theory)? Is it value for money (practice)?

Stroke reduction of 19% (95% CI 2% to 34%)

Risk reduction of 62% (95% CI 48% to 72%) versus placebo

Questions Is stroke frequent? Is stroke a burden? Is AF a cause of stroke? Is AF frequent? Can we prevent Stroke due to AF? (theory) Can we prevent Stroke due to AF? (practice) Who is candidate for new OAC? How many candidates do we have? Is it value for money (theory)? Is it value for money (practice)?

ONLY IN FEW

Antithrombotic Therapy in AF ACC/AHA/ESC Guidelines 2006 High Risk Rheumatic valve, prior stroke, TIA or SE or 2 risk factors: Age >75 years Hypertension Diabetes mellitus CHF/impaired LV function Moderate Risk (CHADS2) 1 risk factor Age >75 years Hypertension Diabetes mellitus CHF/Impaired LV function Low Risk Age 75 years No additional risk factor VKA INR range 2.0 3.0 VKA INR range 2.0 3.0 or ASA 75-325 mg/d ASA 75-325 mg/d ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. Europace. 2006; 8:651-745.

Oral anticoagulant therapy (%) Modest use of VKAs even in high-risk patients: European Heart Survey* 100 80 60 58 59 64 61 40 20 0 1 2 3 4 CHADS 2 score Nieuwlaat et al. Eur Heart J 2006; Gage et al. JAMA 2001 *5,333 AF patients in 35 countries 2003 2004

Stroke rate (% per year) Stroke risk in AF by CHADS 2 score 20 15 C CHF 1 H Hypertension 1 A Age >75 1 D Diabetes mellitus 1 S 2 TIA/stroke 2 12.5 18.2 10 5 0 8.5 5.9 4 1.9 2.8 n=120 n=463 n=523 n=337 n=220 n=65 n=5 0 1 2 3 4 5 6 CHADS 2 score Fuster et al. Eur Heart J 2006

Questions Is stroke frequent? Is stroke a burden? Is AF a cause of stroke? Is AF frequent? Can we prevent Stroke due to AF? (theory) Can we prevent Stroke due to AF? (practice) Who is candidate for new OAC? How many candidates do we have? Is it value for money (theory)? Is it value for money (practice)?

Now

Later?

Questions Is stroke frequent? Is stroke a burden? Is AF a cause of stroke? Is AF frequent? Can we prevent Stroke due to AF? (theory) Can we prevent Stroke due to AF? (practice) Who is candidate for new OAC? How many candidates do we have? Is it value for money (theory)? Is it value for money (practice)?

Depends on price Italy: 100.000? 300.000? 500.000? 700.000?

Questions Is stroke frequent? Is stroke a burden? Is AF a cause of stroke? Is AF frequent? Can we prevent Stroke due to AF? (theory) Can we prevent Stroke due to AF? (practice) Who is candidate for new OAC? How many candidates do we have? Is it value for money (theory)? Is it value for money (practice)?

According to TA agencies, YES

38 33

Questions Is stroke frequent? Is stroke a burden? Is AF a cause of stroke? Is AF frequent? Can we prevent Stroke due to AF? (theory) Can we prevent Stroke due to AF? (practice) Who is candidate for new OAC? How many candidates do we have? Is it value for money (theory)? Is it value for money (practice)?

GARFIELD! Garfield will document in a standardised, comprehensive and solid way what happens to AF patients globally before during after Such evidence is and will be more and more crucial for policy makers 40

Reducing the Stroke Rate in AF Would be a Great Benefit 15 million strokes annually worldwide 20% of strokes due to AF 1,2 3 million are due to AF RRR of 64% with warfarin 3 2 million are preventable with warfarin therapy 50% of eligible patients treated with warfarin 4 1 million strokes could have been prevented 1 Arch Intern Med 1994; 2 Singer et al Chest 2008; 3 Hart et al Ann Intern Med 2007; 4 Connolly et al Circulation 2007

Research Policy